A paper by @TransPot_ITN ESR Rafael Sánchez Martínez and collaborators, published by Cancer Research is available to read now! 'SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer'. https://t.co/C36CDzeHwX #H2020 #MSCA @HingLeung4

Our final ESRs Syed Umbreen, Annelies van Hemelryk, Marouane Kdadra and Anna Mantsiou have now officially finished working on the @TransPot_ITN. Best of luck to you all! This month we have our final meetings before the project officially ends!

What a happy bunch. First meeting of European Prostate Cancer Alliance bringing together 4 collaboratives with a strong focus on prostate cancer - #TRAIN #TransPot #proEVLifeCycle #ProCaRe. Lots of excellent science and ideas for developing new collaborations supported by the #EU

Mario Cangiano is the latest ESR to leave @TransPot_ITN. Best of luck in your future career Mario! Read about Mario's TransPot research here:

Syeda Afshan and Parmveer Singh are the latest ESRs to leave @TransPot_ITN. Thanks to you both for your hard work on the project! Read about Afshan and Parmveer's TransPot research here:

And just like that, Mina Sattari from @TampereUni is our fourth ESR to leave @TransPot_ITN. A big thanks to Mina for her contribution and hard work on the project! Read about Mina's TransPot research here:

Cathal Mc Kinney from @AlmacGroup is our third ESR to leave @TransPot_ITN . Thanks Cathal for your hard work on the project! Read about Cathal's TransPot research here: https://t.co/VACO1AxN40 and here:

Ingrid Tomljanovic is our second ESR to leave TransPot. Thank you Ingrid for your participation in @TransPot_ITN and good luck in your next role in the @proevlifecycle ITN! Read about Ingrid's TransPot research here: https://t.co/VACO1AxN40 and here:

The time has come for our first ESR to leave the project. Thank you Rafael Sanchez Martinez for all of your hard work on TransPot! You can read about Rafael's research here: https://t.co/lUbGNAnnQb and here:

#numares Identifies New Urinary #Biomarkers which Could Detect Aggressive #ProstateCancer. Research of @TransPot_ITN in #InnovationRadar of @EU_Commission. A real potential to impact clin. management of #CRPC (@HingLeung4) https://t.co/yL1sM7vXFq #CancerAlert #prostate #cancer

A new metabolite panel as a chance for improved #diagnostics in #prostatecancer. Urinary #biomarkers – related to #CRPC development – might differentiate indolent/aggressive #PCa. Great lecture by @marouanekd at the @TransPot_ITN symposium: https://t.co/9Mzpkt9W66 (2:33:00)

Our TransPot Symposium yesterday was a great success. About 60 people attended from across Europe and beyond. We express sincere thanks to everyone involved in this successful event. The recording of the Symposium will be available soon on our social media platforms :)

Proud to contribute to #cancer research as part of #TransPot #Horizon2020 program. Thanks to our colleague Marouane Kdadra (@marouanekd) for his important work in #prostatecancer research. Hope to make a change in #PCA #diagnostics together with the gorgeous @TransPot_ITN team!

TransPot are hosting a Symposium! Join us on Wednesday 27th May for talks on Integrated prostate cancer research across the European Union. Further details and registration info can be found on our website: https://t.co/H2RqtxbweE #msca #euresearch #prostatecancer

📣UofG researchers: Join our Overseas Team for a webinar on remaining calls in EU's Horizon 2020 🇪🇺 Find out what's left in H2020, including ERC Advanced Grants, MSCA Fellowships, Future & Emerging Technologies ⏰ 2 April at 10am To register email: rso-eufunding@glasgow.ac.uk'

To all the amazing women in the TransPot Consortium...Happy #InternationalWomenDay

It's #WorldCancerDay2020 today. Search for the hashtag #IAmAndIWill to learn about the different people involved with cancer and cancer research across the world! You can learn more about our work on #ProstateCancer here: https://t.co/lUbGNAnnQb #TransPot #ProstateCancer

Now we are on Youtube 🙂 Subscribe to our channel https://t.co/Zy0Njuaa9t

Another exciting paper from the Prostate Cancer Biology group @HingLeung4 in @oncogenejournal linking the transcription factor BRF1 to reduced immune infiltration and a poor prognosis in prostate cancer. https://t.co/ubAi026cnv

BREAKING: A new type of immunotherapy treatment has just been shown to extend the lives of men with advanced prostate cancer for up to two years. Here we go behind the headlines and explain why we're funding more immunotherapy research this Christmas. 👇 https://t.co/xtQX5q0q7H